Introduction
Since its introduction ipratropium bromide has been recommended for the treatment of chronic bronchitis (Crompton, 1980) but its place in the management of reversible airflow obstruction remains uncertain (Cole, 1981) and it is not clear whether the combination with a 2 agonist has any advantage over individual drugs.
This study sought to determine whether the combination of ipratropium bromide and fenoterol produced greater bronchodilator response than fenoterol alone in patients with chronic asthma.
Patients and methods
Nine patients of mean age 56 (45-66) attending the Asthma Clinic took part in a single-dose, doubleblind crossover study which had the approval of the Hospital's Ethical Committee. All gave a history of chronic or episodic wheeze and their forced expiratory volume in one second (FEV,) improved by 15% or more after two puffs isoprenaline or salbutamol.
Their initial FEV, was less than 80% predicted and all had good timing of aerosol release. They attended on three separate occasions a week apart and omitted bronchodilator therapy for 9 hr before attendance; none was receiving a slow-release oral theophylline preparation. Nine continued to take inhaled steroids, six oral corticosteroids and one sodium cromoglycate. Two patients had positive prick skin tests to common allergens.
After baseline measurements of FEV, forced vital capacity (FVC) (Vitalograph-best of three readings) and pulse rate, they received four puffs of aerosol on each occasion at the same time of day from masked inhalers according to a randomized plan.
The dose of ipratropium bromide used in the combination was higher than the manufacturer's recommended dose, as suggested by Allen and Campbell (1979) . This was compared with two doses of fenoterol; 400 jLg being the recommended dose and 200,ug matching the dose in the combination.
Treatment day A: 2 puffs x 100 ytg fenoterol + 2 puffs x 40 ytg ipratropium; B: 2 puffs x 200 ,tg fenoterol + 2 puffs placebo; C: 2 puffs x 100 ,ug fenoterol + 2 puffs placebo. Patients inhaled at their usual inspiratory flow rate from residual volume to total lung capacity; breathholding time was 4 sec. Aerosol release was patientactivated. Subsequent measurements of pulse, FEV, and FVC were made at 1, 1, 2, 3, 4, 5, 6 and 7 hr after aerosol administration, the latter being expressed as litres (ATPS) .
Statistical analysis of absolute change was by analysis of variance (Table 1) There were no significant differences in mean absolute change in pulse rate between any of the three treatment days.
Discussion
Prolonged effect is a desirable property for an aerosol bronchodilator. Fenoterol hydrobromide has been shown to have a significant effect up to 4 hr in recommended dosage (Plit et al., 1972; Lawford, Dowd and Palmer, 1981) although there is some evidence of longer duration (Anderson, Wilkins and Jariwalla, 1979; Benjamin, 1972) . Ipratropium bromide has likewise been found to have a significant bronchodilator effect up to 4 hr (Gross, 1975) in a dosage of 20 ,ig and a significant prolongation of response with higher dosage (Baigelman and Chodosh, 1977; Allen and Campbell, 1979 Although an additive effect on peak bronchodilator response has been shown for a combination of wet nebulized atropine and salbutamol using cumulative dosing (Pierce, Allen and Campbell, 1979) , and for ipratropium and salbutamol using a sequential study in bronchitis (Douglas et al., 1979) and over a 3 day period in both an asthmatic and bronchitic group (Lightbody et al., 1978) no significant increase in duration of response has been found in single dose studies combining ipratropium and f2 agonist compared to either drug alone (Petrie and Palmer, 1975; Ruffin, Fitzgerald and Rebuck, 1977) .
Further combination studies are needed in patients with steroid-unresponsive airflow obstruction, particularly as ipratropium may produce a comparable or greater response in chronic bronchitis than 82 sympathomimetic drugs (Altounyan, 1964; Crompton, 1968; Poppius and Salorinne, 1973) . 
